01 / DESIGN
What was studied?
This 12-month study enrolled 404 people with HIV and excess abdominal fat. After a six-month randomized phase, participants receiving tesamorelin were rerandomized to continue or change to placebo, while the initial placebo group changed treatment.
02 / FINDINGS
What did the researchers report?
The initial comparison showed reduced visceral fat with tesamorelin. The extension examined maintenance and reversal of that response, alongside body image, IGF-I, glucose and safety measurements.
03 / LIMITS
How should it be interpreted?
Extension results answer a continuation question and should not be presented as a permanent change after stopping. This publication reports a particular phase 3 trial, distinct from the earlier 412-participant study. Neither trial establishes equivalence of laboratory catalog vials to the pharmaceutical study product.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.